Results 21 to 30 of about 10,543,784 (217)

The impact of LncRNA dysregulation on clinicopathology and survival of pancreatic cancer: a systematic review and meta-analysis (PRISMA compliant)

Cancer Cell International, 2021
Purpose An increasing number of studies have reported a significant association between long non-coding RNAs (lncRNAs) dysregulation and pancreatic cancers.
Elahe Seyed Hosseini, Ali Nikkhah, Amir Sotudeh, Marziyeh Alizadeh Zarei, Fatemeh Izadpanah, Hossein Nikzad, Hamed Haddad Kashani   +6 more
doaj   +1 more source

Comparison of survival outcomes between modified radical mastectomy and breast conserving surgery in early breast cancer patients [PDF]

Kosin Medical Journal, 2016
Objectives Breast conserving surgery (BCS) for early breast cancer is now an accepted treatment, but there are controversies about its comparability with mastectomy.
Yoon Seok Kim, Dong Won Ryu, Chung Han Lee   +2 more
doaj   +1 more source

Prognostic Role of Tetraspanin CD81 in Patients with Acute Myeloid Leukemia [PDF]

Zagazig University Medical Journal, 2021
Background. Acute myeloid leukemia (AML) is characterized by clonal expansion of undifferentiated myeloid precursors, resulting in impaired hematopoiesis and bone marrow failure.
ola Hussein, Rana Ahmed, Ayman Fathy, Hossam Salah   +3 more
doaj   +1 more source

(A) Overall survival curve. (B) Disease-free survival curve.

, 2021
(A) Overall survival curve. (B) Disease-free survival curve.
Po-Jung Chen (6501206), Jaw-Yuan Wang (184150), Wei-Chih Su (6478313), Yen-Cheng Chen (334410), Ching-Wen Huang (202294), Tzu-Chieh Yin (9530335), Tsung-Kun Chang (6478307), Ching-Chun Li (9366232), Hsiang-Lin Tsai (428295), Chun-Ming Huang (39301)   +9 more
core   +1 more source

Recurrent Ameloblastoma: Clinical Manifestation and Disease-Free Survival Rate

Journal of Oncology, 2022
Objectives. Ameloblastoma is a slow-growing epithelial odontogenic neoplasm of the jaws with a high recurrence rate. The main treatment strategies for this lesion are radical or conservative surgical approaches. The aim of the present study was to analyze clinical presentations, histological types, and treatment strategies of recurrent ameloblastoma ...
Andrii Hresko, Roman Palyvoda, Olha Burtyn, Yurii Chepurnyi, Andrii Kopchak, Marco Helder, Tymour Forouzanfar   +6 more
openaire   +4 more sources

Multivariate Cox Survival Analysis - Disease-free survival.

, 2013
Multivariate Cox Survival Analysis - Disease-free survival.
Hans-Juergen Holzhausen (303448), Joerg Weimer (303436), Beyhan Ataseven (303437), Keyur Mehta (303432), Norbert Arnold (112045), Sigrid Hamann (303435), Antonia Sophie Wenners (303431), Berit Mueller (303434), Silvia Darb-Esfahani (110661), Gunther von Minckwitz (303451), Maret Bauer (303454), Christian Schem (303438), Carsten Denkert (11194), Hyerim Park (303433), Sibylle Loibl (11099), Christoph Thomssen (303445), Walter Jonat (157379), Christoph Mundhenke (303439), Fariba Khandan (303442)   +18 more
core   +1 more source

Disease-Free Survival.

, 2014
Disease-Free Survival.
Stanley L. Liauw (507756), Gene-Fu F. Liu (507754), Eric Bair (55923), Ryan J. Bair (507755), Matthew Koshy (460252)   +4 more
core   +1 more source

Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed

Nature Reviews Clinical Oncology, 2023
Composite outcome measures such as progression-free survival and disease-free survival are increasingly used as surrogate end points in oncology research, frequently serving as the primary end point of pivotal trials that form the basis for FDA and EMA approvals. Such outcome measures combine two or more distinct events (for example, tumour (re)growth,
Anushka Walia, Jordan Tuia, Vinay Prasad
openaire   +4 more sources

Kaplain-Meier cumulative survival curves for (A) overall survival, (B) disease-free survival, and (C) distant metastasis-free survival.

, 2013
Kaplain-Meier cumulative survival curves for (A) overall survival, (B) disease-free survival, and (C) distant metastasis-free survival.
Jia-Yuan Sun (406033), Zhen-Yu He (406032), Qin Lin (406035), Xun-Xing Guan (406036), San-Gang Wu (406031), Qun Li (222962), Feng-Yan Li (406034), Huan-Xin Lin (131044)   +7 more
core   +1 more source

Kaplan-Meier estimates of disease-free survival (A), relapse-free survival (B), and overall survival (C).

, 2015
Kaplan-Meier estimates of disease-free survival (A), relapse-free survival (B), and overall survival (C).
Hideki Takemura (691534), Yuichiro Higaki (691540), Shigemichi Iwae (691541), Takahide Taguchi (691536), Satoshi Teramukai (386488), Masanori Fukushima (457544), Yasuhisa Hasegawa (691533), Yutaka Hanamure (691543), Tomonori Terada (691535), Takeshi Beppu (691542), Kiyoaki Tsukahara (691531), Kunitoshi Yoshino (691539), Kunihiko Nagahara (691537), Kazuyoshi Kawabata (691546), Masato Fujii (691547), Akira Kubota (691532), Naoyuki Kohno (691545), Kichinobu Tomita (691544), Hiroaki Nakatani (691538)   +18 more
core   +1 more source